NASDAQ:HURA

TuHURA Biosciences Q4 2025 Earnings Results & Report

TuHURA Biosciences logo
$1.41 +0.01 (+0.71%)
As of 01:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TuHURA Biosciences missed analyst earnings expectations in its Q4 2025 results, released March 31, 2026. The company reported EPS of -$0.13 versus the -$0.1233 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

TuHURA Biosciences EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.1233
Beat/Miss
Missed by -$0.0067
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Q4 2025 Earnings FAQ

TuHURA Biosciences (NASDAQ:HURA) reported earnings of -$0.13 per share for Q4 2025, missing the consensus estimate of -$0.1233. The report was announced on Tuesday, March 31, 2026.

TuHURA Biosciences Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack.

The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

TuHURA became a publicly traded company following its 2024 merger with Kintara Therapeutics. The company is based in Tampa, Florida, and is led by President and Chief Executive Officer James Bianco.

View TuHURA Biosciences Profile